Home › Skin Cancer › NCT06675643
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
RecruitingObservational study
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Any skin cancer/melanoma patient starting dual \[ipilimumab/nivolumab (IPI/NIVO)\] immune checkpoint inhibitor (ICI) therapy Exclusion Criteria: * Does not meet inclusion criteria
About the study
This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.
What is being tested
- Non-Interventional Study (other)
Sponsor: Mayo Clinic · Participants: 100 · Started: Oct 14, 2024
Contact the study team
- Clinical Trials Referral Office · Phone: 855-776-0015
- Renee Bradshaw · Phone: 507-284-2511
Official record on ClinicalTrials.gov — NCT06675643
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.